Clinical utility of circulating tumor cell counting through cellsearch®: The dilemma of a concept suspended in limbo

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 619-625

  Raimondi, Cristina ^a   Gradilone, Angela ^a   Naso, Giuseppe ^a   Cortesi, Enrico ^a   Gazzaniga, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Clinical trials; CTC; Prognosis

Indexed keywords

BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; DISEASE MARKER; HUMAN; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; REVIEW; TREATMENT RESPONSE;

EID: 84899137277     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S46200     Document Type: Review

References (31)

1. Cristofanilli M., Budd GT, Ellis MJ, et al. CTC, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351: 781-791.
2. Bidard FC, Fehm T, Ignatiadis M, et al. Clinical application of CTC in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013;32(1-2):179-188.
3. SABCS.org [homepage on the Internet]. The San Antonio Breast Cancer Symposium. Dec 2013. Available from: http://www.sabcs.org. Accessed February 21, 2014.
4. Fehm T, Müller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403-412.
5. Pestrin M, Bessi S, Puglisi F, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive CTC. A proof-of-concept study. Breast Cancer Res Treat. 2012;134(1): 283-289.
6. Paoletti C, Connelly M, Chianese D, et al. Development of circulating tumor cell-endocrine therapy index in metastatic breast cancer patients. Proceedings of the San Antonio Breast Cancer Symposium. Cancer Res. 2011;25.
7. Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) counting as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned fnal analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract]. J Clin Oncol. 2011;29(Suppl 18):LBA4517.
8. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW. All circulating EpCAM+ CK+ CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol. 2010;21(9):1851-1857.
9. Gradilone A, Iacovelli R, Cortesi E, et al. CTC and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma. Anticancer Res. 2011;31(12):4219-4221.
10. Mego M, De Giorgi U, Dawood S, et al. Characterization of meta-static breast cancer patients with nondetectable CTC. Int J Cancer. 2011;129(2):417-423.
11. Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare CTC. Sci Transl Med. 2013;5(179): 147-179.
12. Rossi E, Basso U, Celadin R, et al. M30 neoepitope expression in epithelial cancer: quantifcation of apoptosis in CTC by CellSearch analysis. Clin Cancer Res. 2010;16(21):5233-5243.
13. Smerage JB, Budd GT, Doyle G V, et al. Monitoring apoptosis a Bcl-2 on CTC in patients with metastatic breast cancer. Mol Onc 2013;7(3):680-692.
14. Hou JM, Greystoke A, Lancashire L, et al. Evaluation of CTC a serological cell death biomarkers in small cell lung cancer patie undergoing chemotherapy. Am J Pathol. 2009;175(2):808-816.
15. Edge SB, Byrd DR, Compton CC, et al, editors. AJCC Cancer Stagi Manual. 7th ed. New York, NY: Springer; 2010:347-376.
16. Torino F, Bonmassar E, Bonmassar L, et al. CTC in colorectal can patients. Cancer Treat Rev. 2013;39(7):759-772.
17. Thorsteinsson M, Jess P. The clinical signifcance of CTC in non-metasta colorectal cancer - a review. Eur J Surg Oncol. 2011;37(6):459-465.
18. Bidard FC, Ferrand FR, Huguet F, et al. Disseminated and CTC in gast intestinal oncology. Crit Rev Oncol Hematol. 2012;82(2):103-115.
19. Sastre J, Maestro ML, Puente J, et al. CTC in colorectal canc correlation with clinical and pathological variables. Ann Onc 2008;19(5):935-938.
20. Maestro LM, Sastre J, Rafael SB, et al. CTC in solid tumor in metasta and localized stages. Anticancer Res. 2009;29(11):4839-4843.
21. Thorsteinsson M, Söletormos G, Jess P. Low number of detectable C in non-metastatic colon cancer. Anticancer Res. 2011;31(2):613-61
22. Gazzaniga P, Gianni W, Raimondi C, et al. CTC in high-risk nonmetasta colorectal cancer. Tumour Biol. 2013;34(5):2507-2509.
23. Rack BK, Schindlbeck C, Andergassen U, et al. Use of circulating tum cells (CTC) in peripheral blood of breast cancer patients before a after adjuvant chemotherapy to predict risk for relapse: the SUCCE trial. [abstract]. J Clin Oncol. 2010;28 Suppl 15:1003.
24. Franken B, de Groot MR, Mastboom WJ, et al. CTC, disease recurren and survival in newly diagnosed breast cancer. Breast Cancer R 2012;14(5):R133.
25. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in no metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13(688-695).
26. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzum in combination with neoadjuvant anthracycline-taxane-bas chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 tri Lancet Oncol. 2012;13(2):135-144.
27. Bidard FC, Belin L, Delaloge S, et al. Time-dependent prognostic imp of circulating tumor cells detection in non-metastatic breast canc 70-month analysis of the REMAGUS02 study. Int J Breast Canc 2013;2013:130470.
28. Naoe M, Ogawa Y, Morita J, et al. Detection of circulating urothel cancer cells in the blood using the CellSearch System. Canc 2007;109(7):1439-1445.
29. Rink M, Chun FK, Minner S, et al. Detection of circulating tumour ce in peripheral blood of patients with advanced non-metastatic blad cancer. BJU Int. 2011;107(10):1668-1675.
30. Gazzaniga P, Gradilone A, de Berardinis E, et al. Prognostic value CTC in nonmuscle invasive bladder cancer: a CellSearch analys Ann Oncol. 2012;23(9):2352-2356.
31. Bidard FC, Peeters D, Fehm T, et al. Clinical validity of circulati tumour cells in patients with metastatic breast cancer: a pooled analy of European studies. Lancet Oncol. In press 2014.